top of page

Ambulero will file an IND for our lead gene therapy product AMB-301 by late 2024.


Ambulero is a pioneer in the use of gene and cell therapy approaches to enhance expression of a key cell adhesion molecule (E-selectin) to treat vascular disease and non-healing wounds. We are pleased to announce our commitment to file an Investigational New Drug (IND) application for our lead product, AMB-301, by late 2024. Once achieved, this significant milestone will bring us closer to testing this  gene therapy drug in the clinic.  

Investment Background and National Recognition:

  • Initial start-up funding, management, and business support provided by Ventac Holding, LLC

  • Dr. Omaida Velazquez and Zhao-Jun Liu’s research supported for over a decade by grants from the NIH including funding from the prestigious Vascular Interventions/Innovations and Therapeutic Advances (VITA) program, as well as the Catalyze program of NHLBI

  • The research work of Dr. Velazquez and Dr. Liu supported by the  Wallace H. Coulter Center for Translational Research at the University of Miami

  • Dr. Velazquez inducted into the American Academy of Medicine for groundbreaking research that forms the basis of Ambulero’s cell and gene therapy platform


For more information see the following links :

  1. Ventac Partners

  2. VITA Program

  3. NHLBI Catalyze Program 

  4. Wallace H. Coulter Foundation  

  5. Coulter Center, University of Miami

  6. National Academy of Medicine News  

bottom of page